Orhan A.
- Country
- Germany
- Department
- Klinik fur Neurologie
Research Overview
- Evaluation of Satralizumab Efficacy and Safety in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Phase III Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety of Tolebrutinib in Primary Progressive Multiple Sclerosis: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Phase 3 Randomized, Double-Blind Study of Frexalimab Versus Teriflunomide in Adults with Relapsing Multiple Sclerosis
Data & Insights
Has run more than one trial at 66 of 191 partner sites.
Specializations
Neurological Disorders
The investigator specializes in studying Primary Progressive Multiple Sclerosis (PPMS), focusing on innovative therapeutic approaches for managing this challenging neurological condition.
- Progressive Neurological Diseases
- Multiple Sclerosis Treatment Innovation
- Neurodegenerative Disorders
Their research encompasses neurological disability progression and novel therapeutic interventions in multiple sclerosis.
Therapeutic Development
The investigator focuses on evaluating Bruton's Tyrosine Kinase (BTK) inhibitors as potential treatments for progressive neurological conditions.
- Novel Treatment Mechanisms
- Disease Modification Strategies
- Therapeutic Efficacy Assessment
Their work involves investigating new therapeutic pathways for managing progressive neurological disorders.
Clinical Outcomes
The investigator evaluates interventions aimed at delaying disability progression in neurological conditions.
- Disability Assessment
- Disease Progression Markers
- Treatment Response Evaluation
Their research focuses on measuring and improving functional outcomes in progressive neurological disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.